Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3191 Determination of somatostatin receptors types 2A and 5 (SSTR-2A, SSTR-5) expression in neuroendocrine tumors (NETs) and neuroendocrine carcinoma (NECs) of various localizations and grade

Introduction: One of the main treatment options for this disease is SA,which bind SSTRs to the on the surface of neuroendocrine cells (NC) and block them.But SSTRs are not always present in NC

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Emelianova G, Artamonova E, Ushakov A, Delektorskaya V, Markovich A,

Keywords: neuroendocrine tumor, neuroendocrine carcinoma, somatostatin receptor,

#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors

Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Emelianova G, Dronova E,

Keywords: neuroendocrine tumor, pancreas, sunitinib, somatostatin analogues,

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

#2082 Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors

Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Kuznetsova A, Gorbunova V, Orel N, Emelianova G, Markovich A,

Keywords: lung neuroendocrine tumors, Everolimus,

#1338 Use of Lanreotide LAR in the Case of Intolerance of Octreotide LAR in Patients Well-differentiated NETs

Introduction: Intolerance of Octreotide is about 10 % of cases

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Gorbunova V, Orel N, Emelianova G, Kuzminov A, Markovich A,

Keywords: Octreotide, Lanreotide, intolerance, NETs,